-

Incyte to Report Second Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 1, 2023.

The schedule for the press release and conference call/webcast is as follows:

  • Q2 2023 Press Release: August 1, 2023 at 7:00 a.m. ET
  • Q2 2023 Conference Call: August 1, 2023 at 8:00 a.m. ET
  • Domestic Dial-In Number: 877-407-3042
  • International Dial-In Number: 201-389-0864
  • Conference ID Number: 13739925

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13739925.

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Contacts

Incyte Contacts
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Greg Shertzer
+1 302 274 4779
gshertzer@incyte.com

Incyte

NASDAQ:INCY

Release Versions

Contacts

Incyte Contacts
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Greg Shertzer
+1 302 274 4779
gshertzer@incyte.com

More News From Incyte

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates...

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026...

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer...
Back to Newsroom